Education
About Us
Working with TipRanks
Follow Us
Beam Therapeutics (BEAM)
NASDAQ:BEAM
BEAM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$13.53 - $35.25
Previous CloseN/A
Volume491.48K
Average Volume (3M)2.57M
Market Cap
$2.04B
Enterprise Value$1.36B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.39
Next Earnings
Aug 12, 2025EPS Estimate
-1.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.24
Shares Outstanding100,557,090
10 Day Avg. Volume1,728,864
30 Day Avg. Volume2,571,150
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.55
Forecast
1Y Price Target
$45.87Price Target Upside182.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressBeam announced positive first-in-human in vivo editing data from their Phase 1/2 trial with BEAM-302 in alpha-1 antitrypsin deficiency.
FDA And Regulatory EnvironmentThere is an expectation that Beam Therapeutics' programs could benefit from the FDA's increasingly favorable view on rare diseases.
Financial PositionBeam is backed by a strengthened balance sheet with a cash position of $1.2B, including proceeds from a $500M oversubscribed financing, entering a catalyst-rich period with runway into 2028.
Bears Say
Competition In Treatment DevelopmentAATD is a crowded space with multiple types of treatment modalities in development.
Financial PerformanceNet loss per share was reported as ($1.24) compared to the consensus of ($1.18).
Regulatory ChallengesFollowing the appointment of Vinay Prasad as the next Director of CBER, headwinds are expected for the gene editing space, especially for stocks valued at over $1 billion in market cap.
---
Ownership Overview
21.89% Insiders
13.73% Mutual Funds
0.06% Other Institutional Investors
40.93% Public Companies and
Individual Investors
BEAM FAQ
What was Beam Therapeutics’s price range in the past 12 months?
Beam Therapeutics lowest stock price was $13.53 and its highest was $35.25 in the past 12 months.
What is Beam Therapeutics’s market cap?
Beam Therapeutics’s market cap is $2.04B.
When is Beam Therapeutics’s upcoming earnings report date?
Beam Therapeutics’s upcoming earnings report date is Aug 12, 2025 which is in 95 days.
How were Beam Therapeutics’s earnings last quarter?
Beam Therapeutics released its earnings results on May 06, 2025. The company reported -$1.24 earnings per share for the quarter, missing the consensus estimate of -$1.184 by -$0.056.
Is Beam Therapeutics overvalued?
According to Wall Street analysts Beam Therapeutics’s price is currently Undervalued.
Does Beam Therapeutics pay dividends?
Beam Therapeutics does not currently pay dividends.
What is Beam Therapeutics’s EPS estimate?
Beam Therapeutics’s EPS estimate is -1.12.
How many shares outstanding does Beam Therapeutics have?
Beam Therapeutics has 100,557,090 shares outstanding.
What happened to Beam Therapeutics’s price movement after its last earnings report?
Beam Therapeutics reported an EPS of -$1.24 in its last earnings report, missing expectations of -$1.184. Following the earnings report the stock price went down -19.324%.
Which hedge fund is a major shareholder of Beam Therapeutics?
Currently, no hedge funds are holding shares in BEAM
---
Beam Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.87 (182.80% Upside)
$45.87 (182.80% Upside)
Blogger Sentiment
Bullish
BEAM Sentiment 66%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 852.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 2.4%
Last 30 Days ▲ 2.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-29.80%
12-Months-Change
Fundamentals
Return on Equity
-38.04%
Trailing 12-Months
Asset Growth
7.88%
Trailing 12-Months
Company Description
Beam Therapeutics
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
---
BEAM Stock 12 Month Forecast
Average Price Target
$45.87
▲(182.80% Upside)
Technical Analysis
---